Virgin Olive Oil and Prebiotics Team Up to Fight Muscle Loss in Older Adults
A completed trial tests whether phenolic-rich olive oil plus FOS and inulin can reverse sarcopenia and cut cardiovascular risk in 60–80-year-olds.
Summary
Sarcopenia — the age-related loss of muscle mass and strength — affects millions of older adults and sharply raises the risk of falls, disability, and cardiovascular disease. The FOOP-Sarc trial tested a dual dietary strategy in home-dwelling adults aged 60–80 who already showed signs of sarcopenia. Participants consumed either a refined olive oil (control), a virgin olive oil rich in natural polyphenols including hydroxytyrosol and tyrosol, or that same olive oil combined with prebiotic fibers (fructooligosaccharides and inulin). The 12-week intervention was followed by a 12-week washout to test whether benefits persisted. Researchers tracked muscle mass, grip strength, gait speed, inflammation, oxidative stress, endothelial function, and gut microbiota composition. The study also used cellular models to explore underlying mechanisms and involved participants in co-creating dietary recommendations — a patient-centered design feature rarely seen in nutrition trials.
Detailed Summary
Sarcopenia — the progressive decline in skeletal muscle mass and function that begins in the sixth decade of life — is one of the most consequential yet underappreciated drivers of frailty, falls, and loss of independence in older adults. It is also tightly linked to cardiovascular disease risk, creating compounding health burdens. Effective dietary strategies that can slow or reverse sarcopenia remain an urgent unmet need.
The FOOP-Sarc trial, completed by researchers at the University Rovira i Virgili in Spain, addressed this gap by testing a Mediterranean-inspired dietary approach in sarcopenic adults aged 60–80. Participants were randomly assigned to consume a refined olive oil (control, 38.6 mg hydroxytyrosol and tyrosol per kg oil), a virgin olive oil (VOO) rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol per kg oil), or the phenolic-rich VOO combined with prebiotic supplementation using fructooligosaccharides and inulin. The 12-week active intervention was followed by a 12-week follow-up period to assess whether any gains persisted after stopping the intervention.
Primary outcomes included changes in skeletal muscle mass, muscle performance, and gait speed — the core diagnostic markers of sarcopenia. Secondary outcomes spanned cardiovascular disease risk factors including systemic inflammation, oxidative stress, and endothelial function, as well as gut microbiota composition. Compliance was verified through urinary biomarkers for olive oil polyphenols and fecal markers for prebiotic intake. In vitro cellular models were also used to probe the biological mechanisms driving any observed effects.
A distinctive feature of FOOP-Sarc was its participatory design: a subset of volunteers co-created personalized nutritional and physical activity recommendations, which were then compared against researcher-generated standard recommendations for adherence and effectiveness.
Because this summary is based solely on the trial registration abstract, specific outcome data are not yet available here. However, the design is scientifically rigorous and clinically meaningful, targeting a high-burden condition with a pragmatic, food-first intervention that could be readily adopted if proven effective.
Key Findings
- Phenolic-rich virgin olive oil (156 mg hydroxytyrosol/tyrosol per kg) was tested as a dietary tool to combat sarcopenia.
- Adding prebiotic fibers (FOS and inulin) to olive oil created a combined gut-muscle axis intervention for older adults.
- Both muscle performance and cardiovascular risk markers were co-primary endpoints, linking musculoskeletal and heart health.
- A 12-week washout phase tested whether dietary benefits persisted after the intervention ended.
- Patient co-creation of nutritional recommendations was embedded in the trial design to boost real-world adherence.
Methodology
Randomized controlled trial with three arms — refined olive oil (control), phenolic-rich VOO, and phenolic-rich VOO plus prebiotics — conducted over 12 weeks with an additional 12-week follow-up in home-dwelling sarcopenic adults aged 60–80. Compliance was objectively verified via urinary and fecal biomarkers. Mechanistic investigation included both clinical measures and in vitro cellular models.
Study Limitations
This summary is based on the trial registration abstract only; full results and outcome data have not been reviewed. As a Phase N/A trial with a dietary design, blinding of participants to olive oil type may be imperfect. Generalizability may be limited to Mediterranean populations or those with access to high-phenolic olive oil.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.